The Institute of Cancer Research, London, has strongly welcomed the approval by the European Commission of the targeted drug olaparib for men with advanced prostate cancers with genetic alterations in BRCA1 or BRCA2.

A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

The Institute of Cancer Research, London, has strongly welcomed the approval by the US Food and Drug Administration (FDA) of the genetically targeted drug olaparib for some men with advanced prostate cancer.